IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i12p7309-d838666.html
   My bibliography  Save this article

Alzheimer’s Disease Association with Metals and Metalloids Concentration in Blood and Urine

Author

Listed:
  • Loreta Strumylaite

    (Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania)

  • Rima Kregzdyte

    (Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania)

  • Odeta Kucikiene

    (Department of Geriatrics, Medical Academy, Lithuanian University of Health Science, LT-44307 Kaunas, Lithuania)

  • Dale Baranauskiene

    (Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania)

  • Vaida Simakauskiene

    (Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania)

  • Rima Naginiene

    (Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania)

  • Gyte Damuleviciene

    (Department of Geriatrics, Medical Academy, Lithuanian University of Health Science, LT-44307 Kaunas, Lithuania)

  • Vita Lesauskaite

    (Department of Geriatrics, Medical Academy, Lithuanian University of Health Science, LT-44307 Kaunas, Lithuania)

  • Reda Zemaitiene

    (Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania)

Abstract

As there is some evidence that the risk for Alzheimer’s disease (AD) is partially attributable to environmental exposure to some metals and metalloids, we examined an association between AD and arsenic, chromium, and selenium in 53 AD patients and 217 controls. Urinary arsenic, blood chromium, and selenium were determined by inductively coupled plasma mass spectrometry. Logistic regression models calculating odds ratios (ORs) and 95% confidence intervals (CI) were used to estimate AD association with arsenic, chromium, and selenium. In AD patients, urinary arsenic and blood chromium were significantly higher, while blood selenium was significantly lower compared to controls. Increased blood selenium was related to a significant decrease in the odds of AD after adjustment for risk factors. Blood selenium per 1 kg × 10 −9 /m 3 × 10 −4 increment was associated with 1.4 times lower risk of AD (OR = 0.71; 95% CI 0.58–0.87). A significant increase in the odds of AD associated with increased blood chromium was also seen in the adjusted model: the OR per 1 kg × 10 −9 /m 3 × 10 −3 chromium increment was 2.39 (95% CI 1.32–4.31). The association of urinary arsenic with the risk of AD was not significant. The data obtained provide evidence that selenium reduces the risk of Alzheimer’s disease, while chromium increases it.

Suggested Citation

  • Loreta Strumylaite & Rima Kregzdyte & Odeta Kucikiene & Dale Baranauskiene & Vaida Simakauskiene & Rima Naginiene & Gyte Damuleviciene & Vita Lesauskaite & Reda Zemaitiene, 2022. "Alzheimer’s Disease Association with Metals and Metalloids Concentration in Blood and Urine," IJERPH, MDPI, vol. 19(12), pages 1-11, June.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:12:p:7309-:d:838666
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/12/7309/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/12/7309/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Hanna Maria Elonheimo & Helle Raun Andersen & Andromachi Katsonouri & Hanna Tolonen, 2021. "Environmental Substances Associated with Alzheimer’s Disease—A Scoping Review," IJERPH, MDPI, vol. 18(22), pages 1-22, November.
    2. Hanna Elonheimo & Rosa Lange & Hanna Tolonen & Marike Kolossa-Gehring, 2021. "Environmental Substances Associated with Osteoporosis–A Scoping Review," IJERPH, MDPI, vol. 18(2), pages 1-17, January.
    3. Michael T. Heneka & Markus P. Kummer & Andrea Stutz & Andrea Delekate & Stephanie Schwartz & Ana Vieira-Saecker & Angelika Griep & Daisy Axt & Anita Remus & Te-Chen Tzeng & Ellen Gelpi & Annett Halle , 2013. "NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice," Nature, Nature, vol. 493(7434), pages 674-678, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Vicky Chou & Richard V. Pearse & Aimee J. Aylward & Nancy Ashour & Mariko Taga & Gizem Terzioglu & Masashi Fujita & Seeley B. Fancher & Alina Sigalov & Courtney R. Benoit & Hyo Lee & Matti Lam & Nicho, 2023. "INPP5D regulates inflammasome activation in human microglia," Nature Communications, Nature, vol. 14(1), pages 1-23, December.
    2. Noah R. Johnson & Peng Yuan & Erika Castillo & T. Peter Lopez & Weizhou Yue & Annalise Bond & Brianna M. Rivera & Miranda C. Sullivan & Masakazu Hirouchi & Kurt Giles & Atsushi Aoyagi & Carlo Condello, 2023. "CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model," Nature Communications, Nature, vol. 14(1), pages 1-23, December.
    3. Monica Laura Zlati & Lucian Puiu Georgescu & Catalina Iticescu & Romeo Victor Ionescu & Valentin Marian Antohi, 2022. "New Approach to Modelling the Impact of Heavy Metals on the European Union’s Water Resources," IJERPH, MDPI, vol. 20(1), pages 1-24, December.
    4. Dao-Gong Zhang & Wen-Qian Yu & Jia-Hui Liu & Li-Gang Kong & Na Zhang & Yong-Dong Song & Xiao-Fei Li & Zhao-Min Fan & Ya-Feng Lyu & Na Li & Hai-Bo Wang, 2023. "Serum/glucocorticoid-inducible kinase 1 deficiency induces NLRP3 inflammasome activation and autoinflammation of macrophages in a murine endolymphatic hydrops model," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    5. Ewa Rudnicka-Drożak & Paulina Drożak & Grzegorz Mizerski & Tomasz Zaborowski & Barbara Ślusarska & Grzegorz Nowicki & Martyna Drożak, 2023. "Links between COVID-19 and Alzheimer’s Disease—What Do We Already Know?," IJERPH, MDPI, vol. 20(3), pages 1-15, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:12:p:7309-:d:838666. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.